Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lessons Learned from the Feasibility Phase of the REvascularization CHoices Among Under-Represented Groups Evaluation (RECHARGE) Trial Program.

American heart journal·2026

Same author

Left Ventricular Ejection Fraction Trajectory and Long-Term Outcomes Following Percutaneous Coronary Intervention for Myocardial Infarction.

JACC. Advances·2026

Same author

Marked underutilization of lipoprotein(a) testing in peripheral artery disease: a national analysis of 8.3 million patients.

American journal of preventive cardiology·2026

Same author

Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension: Statement From the BPA-CTEPH Alliance.

JACC. Cardiovascular interventions·2026

Same author

CalShock: beyond the shock team, building on California's cardiogenic shock system of care.

Heart failure reviews·2026

Same author

Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.

Journal of the American College of Cardiology·2026

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Estrogen-eluting stents.

Sung Kee Ryu¹, Ehtisham Mahmud, Sotirios Tsimikas

¹Division of Cardiology, Department of Internal Medicine, Seoul Eulji Hospital, School of Medicine, Eulji University, Seoul, Republic of Korea.

Journal of Cardiovascular Translational Research

|August 6, 2009

Summary

This summary is machine-generated.

Estrogen-eluting stents were evaluated for coronary artery disease treatment, aiming to reduce restenosis and thrombosis. While promising in animal models, human trials did not show superiority over existing stent types.

More Related Videos

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Related Experiment Videos

Last Updated: Jun 21, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Area of Science:

Cardiovascular Medicine
Biomaterials Science
Interventional Cardiology

Background:

Coronary stenting treats obstructive coronary artery disease, but bare metal stents are limited by restenosis due to neointima formation.
Drug-eluting stents (DES) reduce restenosis but carry a risk of late stent thrombosis.
Estrogen-eluting stents offer potential benefits of reduced restenosis and enhanced reendothelialization.

Purpose of the Study:

To evaluate the efficacy of estrogen-eluting stents in reducing restenosis and stent thrombosis.
To investigate estrogen's mechanisms in preventing smooth muscle cell proliferation and promoting endothelial healing.
To compare estrogen-eluting stents with bare metal stents and DES in clinical settings.

Main Methods:

Review of animal studies demonstrating estrogen's effect on neointimal hyperplasia.
Analysis of an uncontrolled human study on estrogen-coated stents for late lumen loss.
Examination of subsequent randomized clinical trials comparing estrogen-eluting stents to bare metal stents and DES.

Main Results:

Estrogen demonstrated effectiveness in decreasing neointimal hyperplasia in animal models.
An initial human study showed acceptable efficacy in reducing late lumen loss.
Randomized clinical trials failed to demonstrate superiority of estrogen-eluting stents over bare metal stents or DES.

Conclusions:

Estrogen-eluting stents did not prove superior to current treatments in human trials.
Further research is needed to determine optimal estrogen delivery methods and doses.
The viability of estrogen-eluting stents as an alternative to DES requires additional investigation.